keyword
MENU ▼
Read by QxMD icon Read
search

Khanna, dinesh

keyword
https://www.readbyqxmd.com/read/27908301/utility-of-b-type-natriuretic-peptides-in-the-assessment-of-patients-with-systemic-sclerosis-associated-pulmonary-hypertension-in-the-pharos-registry
#1
Lorinda Chung, Robert M Fairchild, Daniel E Furst, Shufeng Li, Firas Alkassab, Marcy B Bolster, Mary Ellen Csuka, Chris T Derk, Robyn T Domsic, Aryeh Fischer, Tracy Frech, Mardi Gomberg-Maitland, Jessica K Gordon, Monique Hinchcliff, Vivien Hsu, Laura K Hummers, Dinesh Khanna, Thomas A Jr Medsger, Jerry A Molitor, Ivana R Preston, Elena Schiopu, Lee Shapiro, Faye Hant, Richard Silver, Robert Simms, John Varga, Virginia D Steen, Roham T Zamanian
OBJECTIVES: To assess the utility of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) in detecting and monitoring pulmonary hypertension (PH) in systemic sclerosis (SSc). METHODS: PHAROS is a multicenter prospective cohort of SSc patients at high risk for developing pulmonary arterial hypertension (SSc-AR-PAH) or with a definitive diagnosis of SSc-PH. We evaluated 1) the sensitivity and specificity of BNP≥64 and NT-proBNP≥210 pg/mL for the detection of SSc-PAH and/ or SSc-PH in the SSc-AR-PAH population; 2) baseline and longitudinal BNP and NT-proBNP levels as predictors of progression to SSc-PAH and/or SSc-PH; 3) baseline BNP≥180, NT-proBNP≥553 pg/mL, and longitudinal changes in BNP and NT-proBNP as predictors of mortality in SSc-PH diagnosed patients...
November 10, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27906797/non-cirrhotic-portal-fibrosis-in-pediatric-population
#2
Vikrant Sood, Bikrant Bihari Lal, Rajeev Khanna, Dinesh Rawat, Chhagan Bihari Sharma, Seema Alam
BACKGROUND: Non-cirrhotic portal fibrosis (NCPF) has been classically described as a disease of young to middle age with limited literature regarding its occurrence, onset or clinical presentation in children. We hereby present a series of 19 patients diagnosed and managed as NCPF in pediatric age group. METHODS: A retrospective review of all the patients presenting to the pediatric hepatology department (age < 18 years) and diagnosed as NCPF was done and data was evaluated...
November 30, 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27790579/pure-titanium-membrane-ultra-ti-%C3%A2-in-the-treatment-of-periodontal-osseous-defects-a-split-mouth-comparative-study
#3
Rashmi Khanna, Rajeev Khanna, Nilesh Dinesh Pardhe, Nancy Srivastava, Manas Bajpai, Shailendra Gupta
INTRODUCTION: Although many different types of Guided Tissue Regeneration (GTR) membranes (resorbable/non-resorbable, including titanium mesh) have been used in the field of Periodontics till now, but this is the first and only clinical study testing the effectiveness of an ultra thin pure Titanium Membrane (Ultra Ti) as a GTR membrane in infra-bony periodontal defects. AIM: To compare the efficacy of GTR in intra-bony defects with newly introduced non-resorbable barrier membrane, made of titanium called "Ultra-Ti (®) GTR Membrane" versus open flap debridement...
September 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27746061/rise-ssc-riociguat-in-diffuse-cutaneous-systemic-sclerosis
#4
Oliver Distler, Janet Pope, Chris Denton, Yannick Allanore, Marco Matucci-Cerinic, Janethe de Oliveira Pena, Dinesh Khanna
: RISE-SSc is a randomized, double-blind, placebo-controlled phase 2 study investigating the efficacy and safety of riociguat in patients with diffuse cutaneous systemic sclerosis (dcSSc). Based on positive results from riociguat trials in patients with pulmonary hypertension and chronic thromboembolic pulmonary hypertension in combination with the known antiproliferative and antifibrotic effects seen in animal models, patients with SSc may benefit from treatment with riociguat. Patients with SSc meeting the ACR/EULAR systemic sclerosis classification criteria with diffuse cutaneous SSc (dcSSc) subset per LeRoy criteria, and a disease duration of less than or equal to 18 months will be randomized to placebo or riociguat 0...
September 28, 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27469583/mycophenolate-mofetil-versus-oral-cyclophosphamide-in-scleroderma-related-interstitial-lung-disease-sls-ii-a-randomised-controlled-double-blind-parallel-group-trial
#5
Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja, Richard Silver, Virginia Steen, Charlie Strange, Robert Wise, Fredrick Wigley, Maureen Mayes, David J Riley, Sabiha Hussain, Shervin Assassi, Vivien M Hsu, Bela Patel, Kristine Phillips, Fernando Martinez, Jeffrey Golden, M Kari Connolly, John Varga, Jane Dematte, Monique E Hinchcliff, Aryeh Fischer, Jeffrey Swigris, Richard Meehan, Arthur Theodore, Robert Simms, Suncica Volkov, Dean E Schraufnagel, Mary Beth Scholand, Tracy Frech, Jerry A Molitor, Kristin Highland, Charles A Read, Marvin J Fritzler, Grace Hyun J Kim, Chi-Hong Tseng, Robert M Elashoff
BACKGROUND: 12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared with placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce longer lasting improvements than cyclophosphamide. METHODS: This randomised, double-blind, parallel group trial enrolled patients from 14 US medical centres with scleroderma-related interstitial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HRCT) criteria...
September 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27465349/diagnosis-management-and-long-term-issues-in-pediatric-budd-chiari-syndrome
#6
Vikrant Sood, Rajeev Khanna, Dinesh Rawat, Seema Alam
No abstract text is available yet for this article.
September 2016: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27370878/an-open-label-phase-ii-study-of-the-safety-and-tolerability-of-pirfenidone-in-patients-with-scleroderma-associated-interstitial-lung-disease-the-lotuss-trial
#7
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold, Eduard Gorina
OBJECTIVE: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This study was designed to evaluate the tolerability of the IPF treatment pirfenidone in SSc-ILD. The known gastrointestinal, skin, and liver adverse events (AE) of pirfenidone are of importance given the involvement of these organs in SSc. METHODS: All patients received pirfenidone and were randomized 1:1 to either a 2- or 4-week titration starting at 801 mg/day and finishing at a maintenance dose of 2403 mg/day...
September 2016: Journal of Rheumatology
https://www.readbyqxmd.com/read/27271811/liver-transplantation-in-lch-risk-reactivation-or-wait-till-decompensation
#8
Rajeev Khanna, Arti Pawaria, Seema Alam, Dinesh Rawat
No abstract text is available yet for this article.
November 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/27163986/effect-of-macitentan-on-the-development-of-new-ischemic-digital-ulcers-in-patients-with-systemic-sclerosis-dual-1-and-dual-2-randomized-clinical-trials
#9
RANDOMIZED CONTROLLED TRIAL
Dinesh Khanna, Christopher P Denton, Peter A Merkel, Thomas Krieg, Franck-Olivier Le Brun, Angelina Marr, Kelly Papadakis, Janet Pope, Marco Matucci-Cerinic, Daniel E Furst
IMPORTANCE: Digital ulcers in patients with systemic sclerosis are associated with pain and poor quality of life. Endothelin-1 promotes vasculopathy in systemic sclerosis after macitentan, an endothelin-1 blocker. OBJECTIVE: To evaluate the efficacy of macitentan in reducing the number of new digital ulcers in patients with systemic sclerosis. DESIGN, SETTING, AND PARTICIPANTS: Two international, randomized, double-blind, placebo-controlled trials (DUAL-1, DUAL-2) were conducted between January 2012 and February 2014...
May 10, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27156934/safety-and-efficacy-of-subcutaneous-tocilizumab-in-adults-with-systemic-sclerosis-fasscinate-a-phase-2-randomised-controlled-trial
#10
RANDOMIZED CONTROLLED TRIAL
Dinesh Khanna, Christopher P Denton, Angelika Jahreis, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan, Yannick Allanore, Janet E Pope, Gabriela Riemekasten, Virginia Steen, Ulf Müller-Ladner, Robert Lafyatis, Giuseppina Stifano, Helen Spotswood, Haiyin Chen-Harris, Sebastian Dziadek, Alyssa Morimoto, Thierry Sornasse, Jeffrey Siegel, Daniel E Furst
BACKGROUND: Systemic sclerosis is a rare disabling autoimmune disease with few treatment options. The efficacy and safety of tocilizumab, an interleukin 6 receptor-α inhibitor, was assessed in the faSScinate phase 2 trial in patients with systemic sclerosis. METHODS: We did this double-blind, placebo-controlled study at 35 hospitals in Canada, France, Germany, the UK, and the USA. We enrolled adults with progressive systemic sclerosis of 5 or fewer years' duration from first non-Raynaud's sign or symptom...
June 25, 2016: Lancet
https://www.readbyqxmd.com/read/27099767/characterisation-of-an-epigenetically-altered-cd4-cd28-kir-t-cell-subset-in-autoimmune-rheumatic-diseases-by-multiparameter-flow-cytometry
#11
Faith M Strickland, Dipak Patel, Dinesh Khanna, Emily Somers, Aaron M Robida, Michael Pihalja, Richard Swartz, Wendy Marder, Bruce Richardson
OBJECTIVES: Antigen-specific CD4(+) T cells epigenetically modified with DNA methylation inhibitors overexpress genes normally suppressed by this mechanism, including CD11a, CD70, CD40L and the KIR gene family. The altered cells become autoreactive, losing restriction for nominal antigen and responding to self-class II major histocompatibility complex (MHC) molecules without added antigen, and are sufficient to cause a lupus-like disease in syngeneic mice. T cells overexpressing the same genes are found in patients with active lupus...
2016: Lupus Science & Medicine
https://www.readbyqxmd.com/read/27078625/lung-transplant-outcomes-in-systemic-sclerosis-with-significant-esophageal-dysfunction-a-comprehensive-single-center-experience
#12
Catherine H Miele, Kristin Schwab, Rajeev Saggar, Erin Duffy, David Elashoff, Chi-Hong Tseng, Sam Weigt, Deepshikha Charan, Fereidoun Abtin, Jimmy Johannes, Ariss Derhovanessian, Jeffrey Conklin, Kevin Ghassemi, Dinesh Khanna, Osama Siddiqui, Abbas Ardehali, Curtis Hunter, Murray Kwon, Reshma Biniwale, Michelle Lo, Elizabeth Volkmann, David Torres Barba, John A Belperio, David Sayah, Thomas Mahrer, Daniel E Furst, Suzanne Kafaja, Philip Clements, Michael Shino, Aric Gregson, Bernard Kubak, Joseph P Lynch, David Ross, Rajan Saggar
RATIONALE: Consideration of lung transplantation in patients with systemic sclerosis (SSc) remains guarded, often due to the concern for esophageal dysfunction and the associated potential for allograft injury and suboptimal post-lung transplantation outcomes. OBJECTIVES: The purpose of this study was to systematically report our single-center experience regarding lung transplantation in the setting of SSc, with a particular focus on esophageal dysfunction. METHODS: We retrospectively reviewed all lung transplants at our center from January 1, 2000 through August 31, 2012 (n = 562), comparing the SSc group (n = 35) to the following lung transplant diagnostic subsets: all non-SSc (n = 527), non-SSc diffuse fibrotic lung disease (n = 264), and a non-SSc matched group (n = 109)...
June 2016: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/27027811/management-of-connective-tissue-diseases-associated-interstitial-lung-disease-a-review-of-the-published-literature
#13
Beth Wallace, Dharshan Vummidi, Dinesh Khanna
PURPOSE OF REVIEW: Interstitial lung disease (ILD), though a common and often a severe manifestation of many connective tissue diseases (CTD), is challenging to manage because of its variable presentation and the relative lack of guidelines to assist the clinician. In this review, we discuss the approach to diagnosis, treatment, and monitoring patients with CTD-associated ILD, with a focus on systemic sclerosis (SSc), rheumatoid arthritis (RA), and idiopathic inflammatory myopathy (IIM)...
May 2016: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/27015290/using-optimal-test-assembly-methods-for-shortening-patient-reported-outcome-measures-development-and-validation-of-the-cochin-hand-function-scale-6-a-scleroderma-patient-centered-intervention-network-spin-cohort-study
#14
Alexander W Levis, Daphna Harel, Linda Kwakkenbos, Marie-Eve Carrier, Luc Mouthon, Serge Poiraudeau, Susan J Bartlett, Dinesh Khanna, Vanessa L Malcarne, Maureen Sauve, Cornelia H M van den Ende, Janet L Poole, Anne A Schouffoer, Joep Welling, Brett D Thombs
OBJECTIVE: The objective was to develop and validate a short form of the Cochin Hand Function Scale (CHFS), which measures hand disability, for use in systemic sclerosis, using objective criteria and reproducible techniques. METHODS: Responses on the 18-item CHFS were obtained from English-speaking patients enrolled in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. CHFS unidimensionality was verified using confirmatory factor analysis, and an item response theory model was fit to CHFS items...
March 25, 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/26888852/performance-of-gout-impact-scale-in-a-longitudinal-observational-study-of-patients-with-gout
#15
Beth Wallace, Dinesh Khanna, Cleopatra Aquino-Beaton, Jasvinder A Singh, Erin Duffy, David Elashoff, Puja P Khanna
OBJECTIVE: The aim was to evaluate the reliability, validity and responsiveness to change of the Gout Impact Scale (GIS), a disease-specific measure of patient-reported outcomes, in a multicentre longitudinal prospective cohort of gout patients. METHODS: Subjects completed the GIS, a 24-item instrument with five scales: Concern Overall, Medication Side Effects, Unmet Treatment Need, Well-Being during Attack, and Concern Over Attack. The total GIS score was calculated by averaging the GIS scale scores...
June 2016: Rheumatology
https://www.readbyqxmd.com/read/26808827/the-american-college-of-rheumatology-provisional-composite-response-index-for-clinical-trials-in-early-diffuse-cutaneous-systemic-sclerosis
#16
RANDOMIZED CONTROLLED TRIAL
Dinesh Khanna, Veronica J Berrocal, Edward H Giannini, James R Seibold, Peter A Merkel, Maureen D Mayes, Murray Baron, Philip J Clements, Virginia Steen, Shervin Assassi, Elena Schiopu, Kristine Phillips, Robert W Simms, Yannick Allanore, Christopher P Denton, Oliver Distler, Sindhu R Johnson, Marco Matucci-Cerinic, Janet E Pope, Susanna M Proudman, Jeffrey Siegel, Weng Kee Wong, Athol U Wells, Daniel E Furst
OBJECTIVE: Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs). METHODS: We developed 150 paper patient profiles with standardized clinical outcome elements (core set items) using patients with dcSSc. Forty scleroderma experts rated 20 patient profiles each and assessed whether each patient had improved or not improved over a period of 1 year...
February 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26806474/the-american-college-of-rheumatology-provisional-composite-response-index-for-clinical-trials-in-early-diffuse-cutaneous-systemic-sclerosis
#17
Dinesh Khanna, Veronica J Berrocal, Edward H Giannini, James R Seibold, Peter A Merkel, Maureen D Mayes, Murray Baron, Philip J Clements, Virginia Steen, Shervin Assassi, Elena Schiopu, Kristine Phillips, Robert W Simms, Yannick Allanore, Christopher P Denton, Oliver Distler, Sindhu R Johnson, Marco Matucci-Cerinic, Janet E Pope, Susanna M Proudman, Jeffrey Siegel, Weng Kee Wong, Athol U Wells, Daniel E Furst
OBJECTIVE: Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs). METHODS: We developed 150 paper patient profiles with standardized clinical outcome elements (core set items) using patients with dcSSc. Forty scleroderma experts rated 20 patient profiles each and assessed whether each patient had improved or not improved over a period of 1 year...
February 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/26792595/genetic-susceptibility-loci-of-idiopathic-interstitial-pneumonia-do-not-represent-risk-for-systemic-sclerosis-a-case-control-study-in-caucasian-patients
#18
Minghua Wu, Shervin Assassi, Gloria A Salazar, Claudia Pedroza, Olga Y Gorlova, Wei V Chen, Julio Charles, Miranda L Taing, Kelley Liao, Fredrick M Wigley, Laura K Hummers, Ami A Shah, Monique Hinchcliff, Dinesh Khanna, Elena Schiopu, Kristine Phillips, Daniel E Furst, Virginia Steen, Murray Baron, Marie Hudson, Xiaodong Zhou, Janet Pope, Niall Jones, Peter Docherty, Nader A Khalidi, David Robinson, Robert W Simms, Richard M Silver, Tracy M Frech, Barri J Fessler, Marvin J Fritzler, Jerry A Molitor, Barbara M Segal, Malahat Movahedian, Javier Martín, John Varga, Maureen D Mayes
BACKGROUND: Systemic sclerosis (SSc)-related interstitial lung disease (ILD) has phenotypic similarities to lung involvement in idiopathic interstitial pneumonia (IIP). We aimed to assess whether genetic susceptibility loci recently identified in the large IIP genome-wide association studies (GWASs) were also risk loci for SSc overall or severity of ILD in SSc. METHODS: A total of 2571 SSc patients and 4500 healthy controls were investigated from the US discovery GWAS and additional US replication cohorts...
2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/26757749/transitions-to-different-patterns-of-interstitial-lung-disease-in-scleroderma-with-and-without-treatment
#19
Hyun J Kim, Donald P Tashkin, David W Gjertson, Matthew S Brown, Eric Kleerup, Semin Chong, John A Belperio, Michael D Roth, Fereidoun Abtin, Robert Elashoff, Chi-Hong Tseng, Dinesh Khanna, Jonathan G Goldin
OBJECTIVES: The aim is to investigate whether the 12-month quantitative changes in high-resolution CT (HRCT) measures of interstitial lung disease (ILD) are different, and to understand how they change, in patients with scleroderma-related ILD who receive drug therapy versus placebo. METHODS: HRCT images were acquired at baseline and at 12 months in 83 participants in Scleroderma Lung Study I, a clinical trial comparing treatment with oral cyclophosphamide versus placebo...
July 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/26705326/scleroderma-dermal-microvascular-endothelial-cells-exhibit-defective-response-to-pro-angiogenic-chemokines
#20
Pei-Suen Tsou, Bradley J Rabquer, Ray A Ohara, William A Stinson, Phillip L Campbell, M Asif Amin, Beatrix Balogh, George Zakhem, Paul A Renauer, Ann Lozier, Eshwar Arasu, G Kenneth Haines, Bashar Kahaleh, Elena Schiopu, Dinesh Khanna, Alisa E Koch
OBJECTIVES: Angiogenesis plays a critical role in SSc (scleroderma). The aim of this study was to examine the expression of growth-regulated protein-γ (Gro-γ/CXCL3), granulocyte chemotactic protein 2 (GCP-2/CXCL6) and their receptor CXCR2 in endothelial cells (ECs) isolated from SSc skin and determine whether these cells mount an angiogenic response towards pro-angiogenic chemokines. The downstream signalling pathways as well as the pro-angiogenic transcription factor inhibitor of DNA-binding protein 1 (Id-1) were also examined...
April 2016: Rheumatology
keyword
keyword
104978
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"